Investors Prepare to Navigate FDA Crosswinds Ahead of the J.P. Morgan Healthcare Conference
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 263: Building NC's Innovation Ecosystem with Andrea Conner of First Flight Venture Center
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 262: Breaking the “Undruggable” Barrier with Marcel Frenkel of Ten63 Therapeutics
Alumni Spotlight: Steve Brown
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 261: Transforming Lives with Advanced BioMaterials with Dr. Juliana Blum of BioAesthetics
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 260: Innovation and Policy in Animal Health with Ron Phillips of the Animal Health Institute
Project Catalyst: An Economic Development Podcast | Episode 18: The Triad’s Economic Momentum with Marvin Price of the Greensboro Chamber of Commerce
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 259: The Patient Voice in Clinical Trials with Tom Croce of Jazz Pharmaceuticals
AGG Talks: Government Insight for Life Sciences Leaders | How Medicare Regulations Could Affect Access to Gender-Affirming Care: Implications for Life Sciences Companies
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 257: Biogen’s $2B Investment in North Carolina’s RTP with Nicole Murphy
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 256: AI, Advocacy & Clinical Trials with Sophia McLeod of ACRO
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 255: Private Equity Essentials for Life Sciences Organizations and Startups
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 254: Responsible AI in Healthcare with Dr. Justin Collier of Lenovo
What's New with the False Claims Act?
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 253: The Rise of Ambulatory Surgery Centers with Mark Wainner of ASCA
AGG Talks: Government Insight for Life Sciences Leaders - Episode 2: DOJ’s Shifting Enforcement: CPB Disbanding, Counterfeit Drug Focus, and Gender-Affirming Care Investigations
Podcast - Part I: Going from Young Associate to Veteran Lawyer
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 252: Navigating Policy and Technology Shifts in MedTech with Bobby Patrick of AdvaMed
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 251: The Future of Public Health with Dr. Georges Benjamin of APHA
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 250: Tariffs, Drug Pricing & Domestic Manufacturing with Gil Roth of PBOA
Our FDA: Drug & Device Team analyzes the Food and Drug Administration’s new guidance on Bayesian approaches to innovative drug trials, providing greater clarity on how companies may design and conduct studies....more
The life sciences M&A market is reemerging in 2026 as a competitive arena for strategic buyers, after several years of subdued activity. ...more
In 2025, the Rx IP Update team at Smart & Biggar reported on a number of developments in Canadian life sciences IP and regulatory law. Highlights from 2025 are below...more
Veritas Capital announced one of its affiliates will acquire a majority stake in Global Healthcare Exchange (GHX). GHX, founded in 2000 and based in Louisville, Colorado, is a supply chain software platform....more
The life sciences industry is poised for an upswing in initial public offering (IPO) activity in 2026, supported by a large IPO backlog, the strong performance of biotech market indices, and positive capital markets signals...more
As early-stage life sciences companies prepare for their next financing or partnership, intellectual property due diligence is often the first, and most consequential, checkpoint. ...more
Morrison Foerster partners Kate Driscoll and Nate Mendell, both former federal prosecutors and members of the firm’s Investigations + White Collar Defense Group, hosted the twelfth episode of When Your Life Sciences Are on...more
The Trump Administration continues to pursue a policy of AI dominance, which began with its January 23, 2025 executive order to remove “barriers” to Artificial Intelligence (“AI”) innovation to promote “human flourishing,...more
A client calls and says, “We’re cooking up a bispecific antibody. We want to mix and match binding sequences like a molecular gastronomy tasting menu. Some will go into CAR-T dishes. And of course, we want patents...more
M&A in the AI Era: What Buyers Can Do to Confirm and Protect Value. Don’t Believe the Hype: Government Regulation of AI Continues to Advance. Structured Finance Is Playing a Key Role as the Capital Demands of Data Center and...more
As the new year begins, we’re excited to share our 2026 Insights. This issue is packed with analysis and forward-looking commentary on some of the key topics we see shaping the global business landscape....more
As we head into what is anticipated to be a strong year for biopharma dealmaking, we look back at some of the biggest deals in 2025 that focus on biologics and biosimilars....more
Happy New Year, Founders! As we enter 2026, I encourage pharmaceutical innovators to approach intellectual property with energy and intention. The start of the year is the perfect time to step back and review your patent...more
Our Life Sciences and MedTech thought leaders have pulled together their top predictions for the new year so that employers can get a running start to 2026....more
There may be no more difficult decision for a business owner than the decision to sell a business. The difficulty in the decision lies not only in the emotion of turning over a life’s work and a career, but also in the number...more
Global investors in AI, machine learning, semiconductors, biotech, and data infrastructure face intersecting regulatory risks that affect talent, supply chains, governance, and exits. Those who integrate immigration, CFIUS,...more
Private capital is poised to remain a driving force in healthcare and life sciences, even as the sector navigates a more complex and competitive environment. After a record-setting surge in 2024 — when global healthcare...more
On December 18, 2025, the FDA approved Formycon and Zydus’s Nufymco™ (ranibizumab-leyk) as the third interchangeable biosimilar of Genentech’s Lucentis® (ranibizumab). Lucentis® biosimilars have been on the market since July...more
FDA Commissioner Marty Makary announced policy shifts that ease the path to market for certain digital health technologies, including AI- and generative AI-enabled clinical decision support software (CDS) and consumer...more
Heading into the J.P. Morgan Healthcare Conference, the conversation will center on accelerated deal flow, selective but improving capital access, and disciplined execution. Strategic buyers face patent cliffs and pipeline...more
Clients & Friends, Looking back on 2025, one word comes to mind: resiliency. The life sciences sector has taken some hits, but it kept moving. Public markets are showing real signs of life again. The private side - frozen...more
Grant Avenue Capital announced it has acquired PatientCare EMS Solutions. PatientCare, founded in 1998 and based in Tyler, Texas, is a provider of ground ambulance services, delivering emergency and non-emergency medical...more
As life sciences companies expand internationally, regulatory readiness must evolve into a strategic capability that supports global business planning and innovation....more
Transitioning from discovery to clinical development marks a defining moment for emerging biotech companies. It’s also a time to consider evolving your IP strategy from protecting ideas to protecting assets....more
This latest edition features articles on reasons for optimism around 2026 life sciences fundraising, key IP priorities for biotech and biopharma following Series B financing, the default rules of joint patent rights...more